share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  08/06 08:08
Moomoo AI 已提取核心信息
On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.
On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.
2024年8月6日,Clene公司通过新闻发布会宣布向美国食品和药物管理局提交CNm-Au8的新型生物标志物和临床疗效数据,以支持其治疗肌萎缩侧索硬化症(ALS)的应用。该公告现已作为附件99.2提交该公司的当前8-k表格。另外,Clene公司还在其投资者关系网站上更新了公司的企业介绍,作为同一报告中的附件99.1提供。该公司已表示未来将通过其网站分发企业介绍的更新,无需提交或提供当前的8-k表格以通知投资者。
2024年8月6日,Clene公司通过新闻发布会宣布向美国食品和药物管理局提交CNm-Au8的新型生物标志物和临床疗效数据,以支持其治疗肌萎缩侧索硬化症(ALS)的应用。该公告现已作为附件99.2提交该公司的当前8-k表格。另外,Clene公司还在其投资者关系网站上更新了公司的企业介绍,作为同一报告中的附件99.1提供。该公司已表示未来将通过其网站分发企业介绍的更新,无需提交或提供当前的8-k表格以通知投资者。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息